IRIS

The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant.

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study / Cazzaniga, M. E; Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, G. V; Blasi, L; Campidoglio, S; Ciccarese, M; Cursano, M. C; Piezzo, M; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Turletti, A; Valerio, M. R; Vici, P; Zambelli, A; Clivio, L; Torri, V.; De Laurentiis, Michelino. - In: THE BREAST. - ISSN 0960-9776. - 35:(2017), p. 115-121. [10.1016/j.breast.2017.06.043]

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

De Laurentiis, Michelino
Membro del Collaboration Group
2017

Abstract

The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant.
2017
THE BREAST
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study / Cazzaniga, M. E; Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, G. V; Blasi, L; Campidoglio, S; Ciccarese, M; Cursano, M. C; Piezzo, M; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Turletti, A; Valerio, M. R; Vici, P; Zambelli, A; Clivio, L; Torri, V.; De Laurentiis, Michelino. - In: THE BREAST. - ISSN 0960-9776. - 35:(2017), p. 115-121. [10.1016/j.breast.2017.06.043]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/694603
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 19
social impact